A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:

A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05658562
• Other study ID #: MT-2111-A-101
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 30, 2023
• Est. completion date: August 2028

Study information

• Verified date: December 2023
• Source: Mitsubishi Tanabe Pharma Corporation
• Contact: Clinical Trials Information Desk
• Phone: please email:
• Email: cti-inq-ml[@]ml.mt-pharma.co.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

[Phase I part] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed.

[Phase II part] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 49
• Est. completion date: August 2028
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who were diagnosed pathologically with DLBCL, NOS, DLBCL transformed from indolent B-cell lymphoma, or high-grade B-cell lymphoma with DLBCL morphology and with MYC and BCL2 and/or BCL6 rearrangements, based on the 2017 WHO classification.

• Patients with relapsed or refractory disease despite 2 or more prior systemic therapies.

• Japanese patients aged = 18 years at the time of informed consent. For Japanese subjects, it should be confirmed that the parents who are related by blood to the subject must be Japanese.

• Patients who have a lesion that can be assessed for staging and evaluated for response according to the Lugano criteria (2014). A lesion that has received radiotherapy as the most recent treatment will be considered as a measurable lesion only when progression has been documented following completion of the radiotherapy.

• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at screening.

Exclusion Criteria:

• Patients with a pathological diagnosis of Burkitt's lymphoma.

• Patients with bulky disease with the longest dimension of = 10 cm.

• Patients with a history or complication of post-transplant lymphoproliferative disorders.

• Patients with lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease.

• Patients complicated with other active malignancies or patients with a history of other malignancies within 3 years before informed consent. However, the following are exceptional:

• Non-melanoma skin cancer

• Non-metastatic prostate cancer

• Cervical carcinoma in situ

• Ductal carcinoma in situ or lobular carcinoma in situ

• Patients with clinically significant third space fluid accumulation (e.g., ascites requiring drainage or pleural effusion requiring drainage or associated with shortness of breath).

• Patients who underwent autologous hematopoietic stem cell transplantation (AHSCT) within 30 days prior to the start of study drug administration (Cycle 1 Day 1).

• For the Phase I part, patients with prior allogeneic stem cell transplantation (Allo-HSCT) before the start of study drug administration (Cycle 1 Day 1). For the Phase II part, patients undergoing Allo-HSCT within 60 days prior to the start of study drug administration (Cycle 1 Day 1).

• Patients who had a positive HIV antigen-antibody test or HIV antibody test.

• Patients positive for HBs antigen, HBc antibody, or HBs antibody. However, patients who meet any of the following are eligible:

• The patient's HBs antibody positivity is clearly due to vaccination.

• Patients who are positive for HBs antibody and/or HBc antibody with HBV-DNA not detected and agree to undergo HBV-DNA tests once a month from the start of study drug administration to at least 12 months after the completion of study drug administration.

• Patients positive for HCV antibody. However, patients with negative HCV-RNA are eligible.

• Patients who received anticancer therapy during the following periods prior to the start of study drug administration (Cycle 1 Day 1).

• Cytotoxic chemotherapy: within 14 days.

• Antibody therapy: within 5 half-lives or 14 days, whichever is longer (including monoclonal antibody preparations, radioimmunoconjugates, or antibody-drug conjugates). Within 14 days for rituximab.

• Radiotherapy: within 14 days

• CAR-T therapy: within 100 days

• Other anticancer therapy: within 14 days

• Patients who received treatment with any other investigational product within 14 days prior to the start of study drug administration (Cycle 1 Day 1). However, for the Phase I part, patients who received any other investigational product within 14 days or 5 half-lives, whichever is longer, before the start of study drug administration (Cycle 1 Day 1).

Related Conditions & MeSH terms

• Diffuse Large B-Cell Lymphoma
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• MT-2111
i.v. infusion

Locations

Country	Name	City	State
Japan	Tokyo Metropolitan Komagome Hospital	Bunkyo-ku	Tokyo
Japan	National Cancer Center Hospital	Chuo-ku	Tokyo
Japan	Kyushu Cancer Center	Fukuoka-shi	Fukuoka
Japan	Shimane University Hospital	Izumo-shi	Shimane
Japan	National Cancer Center Hospital East	Kashiwa-shi	Chiba
Japan	Cancer Institute Hospital of JFCR	Koto-ku	Tokyo
Japan	University Hospital, Kyoto Prefectural University of Medicine	Kyoto-shi	Kyoto
Japan	Shinshu University Hospital	Matsumoto-shi	Nagano
Japan	Japanese Red Cross Nagasaki Genbaku Hospital	Nagasaki-shi	Nagasaki
Japan	Nagoya Medical Center	Nagoya-shi	Aichi
Japan	Gunma Prefectural Cancer Center	Ota-shi	Gunma
Japan	Hokkaido Cancer Center	Sapporo-shi	Hokkaido
Japan	Tohoku University Hospital	Sendai-shi	Miyagi
Japan	Yamagata University Hospital	Yamagata-shi	Yamagata

Sponsors (1)

Lead Sponsor	Collaborator
Mitsubishi Tanabe Pharma Corporation

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR) by independent central review		From the date of first dose of study treatment until all participants completed treatment period or discontinued treatment (Up to 12 months)
Secondary	Duration of response (DOR)		The time from the date of first observation of complete response (CR) or partial response (PR) until progressive disease (PD) or death in patients with CR or PR observed (Up to 48 months)
Secondary	Complete response rate (CRR)		From the date of first dose of study treatment until all participants completed treatment period or discontinued treatment (Up to 12 months)
Secondary	Overall survival (OS)		The time from the date of first dose until death regardless of the occurrence of intercurrent event (Up to 48 months)
Secondary	Progression-free survival (PFS)		The time from the date of first dose until PD or death (Up to 48 months)
Secondary	Relapse-free survival (RFS)		The time from the date of first observation of CR until PD or death in patients with CR observed (Up to 48 months)
Secondary	Adverse events and adverse drug reactions		From the start of premedication until 15 weeks after the last dose of the study drug or until the start of new anticancer therapy, whichever comes first.
Secondary	Eastern Cooperative Oncology Group (ECOG) Performance Status	ECOG (Eastern Cooperative Oncology Group) Performance Status is scored on a 6-point scale where higher scores indicate a worse outcome.	Screening to end of treatment (up to 30 days after the last dose) or data cut off
Secondary	Body weight		Screening to end of treatment (up to 30 days after the last dose) or data cut off
Secondary	12-lead electrocardiogram (heart rate)		Screening to end of treatment (up to 30 days after the last dose) or data cut off
Secondary	12-lead electrocardiogram [RR, PR, QRS, QT (QTcF)]		Screening to end of treatment (up to 30 days after the last dose) or data cut off
Secondary	12-lead electrocardiogram (presence or absence of abnormal findings)		Screening to end of treatment (up to 30 days after the last dose) or data cut off
Secondary	Serum drug concentration	[Phase 1 part] Cycle 1 [each cycle is 3 weeks (21 days) in duration]: Day 1, 2, 5, 8 and 15, Cycle 2: Day 1, 2, 8 and 15, Cycle 3: Day 1 and 8, odd number Cycle: Day 1,end of treatment (EOT)*, and 15 weeks after EOT* [Phase 2 part] Cycle 1 and 2: Day 1, 8 and 15, odd number Cycle : Day 1, EOT*, and15 weeks after EOT*; *: After the decision to discontinue treatment with study drug and prior to the start of any new anticancer therapy, the scheduled evaluations will be performed preferably 30 days after the last dose of study drug.; One cycle is 3 weeks (21 days) in duration.; *: After the decision to discontinue treatment with study drug and prior to the start of any new anticancer therapy, the scheduled evaluations will be performed preferably 30 days after the last dose of study drug.	Please refer to the description above
Secondary	Anti-drug antibodies (including neutralizing antibodies)	[Phase 1 part] Cycle 1 [each cycle is 3 weeks (21 days) in duration]: Day 1 and 15, Cycle 2: Day 1, odd number Cycle: Day 1, end of treatment (EOT)*, and 15 weeks after EOT* [Phase 2 part] Cycle 1: Day 1 and 15, Cycle 2: Day 1, odd number Cycle : Day 1, EOT*, and 15 weeks after EOT*; *: After the decision to discontinue treatment with study drug and prior to the start of any new anticancer therapy, the scheduled evaluations will be performed preferably 30 days after the last dose of study drug.	Please refer to the description above.